Page last updated: 2024-09-02

selenomethylselenocysteine and tirapazamine

selenomethylselenocysteine has been researched along with tirapazamine in 1 studies

Compound Research Comparison

Studies (selenomethylselenocysteine)	Trials (selenomethylselenocysteine)	Recent Studies (post-2010) (selenomethylselenocysteine)	Studies (tirapazamine)	Trials (tirapazamine)	Recent Studies (post-2010) (tirapazamine)
202	6	107	484	44	133

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bhattacharya, A; Cao, S; Chintala, S; Durrani, FA; Rustum, YM; Slocum, HK; Tóth, K	1

Other Studies

1 other study(ies) available for selenomethylselenocysteine and tirapazamine

Article	Year
Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts. Neoplasia (New York, N.Y.), 2008, Volume: 10, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cysteine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forkhead Transcription Factors; Head and Neck Neoplasms; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Organoselenium Compounds; Selenocysteine; Tirapazamine; Triazines; Xenograft Model Antitumor Assays	2008

Article

Year

Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.

Neoplasia (New York, N.Y.), 2008, Volume: 10, Issue:8

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cysteine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forkhead Transcription Factors; Head and Neck Neoplasms; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Organoselenium Compounds; Selenocysteine; Tirapazamine; Triazines; Xenograft Model Antitumor Assays

2008